GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director

GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director

GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015. On appointment, Mr Rohner will also become a member of GSK's Remuneration Committee.

Mr Rohner is currently Chairman of Credit Suisse Group AG, one of the world's leading financial services companies.

Commenting on the appointment, Sir Christopher Gent, Chairman of GSK, said:
"I am delighted to welcome Urs to the Board. His broad business background and extensive senior-level experience at multinational companies makes him a great addition to GSK."

Mr Rohner was appointed Chairman of Credit Suisse in 2011 following a number of senior positions at the company including General Counsel and Chief Operating Officer. Before joining Credit Suisse in 2004, he was Chief Executive Officer and Chairman for four years at ProSiebenSat.1 Group, one of the largest independent media corporations in Europe. This followed a number of years in private practice at major law firms in Switzerland and the USA.

Victoria Whyte

Company Secretary

3 October 2014


Notes

1.     As Non-Executive Director of GSK, Mr Rohner will receive standard annual fees of £85,000 per annum.  As for all GSK Non-Executive Directors, in order to enhance the link between directors and shareholders, at least 25% of his fees will be paid in the form of Ordinary Shares and allocated to a share account, and he will be able to invest part or all of the balance of his fees into the same share account.

2.     The Board has determined that Mr Rohner will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code.

3.     With effect from 1st January 2015, the composition of the Board of GlaxoSmithKline plc will be as    follows:

Sir Christopher Gent                  Non-Executive Chairman

Sir Philip Hampton                    Non-Executive Director and Chairman Designate

Sir Andrew Witty                        Chief Executive Officer

Mr Simon Dingemans                Chief Financial Officer

Dr Moncef Slaoui                      Chairman, Global R&D and Vaccines

Professor Sir Roy Anderson      Independent Non-Executive Director

Dr Stephanie Burns                   Independent Non-Executive Director

Ms Stacey Cartwright                 Independent Non-Executive Director

Ms Lynn Elsenhans                   Independent Non-Executive Director

Ms Judy Lewent                        Independent Non-Executive Director

Sir Deryck Maughan                  Senior Independent Non-Executive Director

Dr Daniel Podolsky                   Independent Non-Executive Director

Mr Tom de Swaan                     Independent Non-Executive Director

Ms Jing Ulrich                           Independent Non-Executive Director

Mr Hans Wijers              Independent Non-Executive Director

Mr Urs Rohner                           Independent Non-Executive Director


GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com


Communications and Government Affairs

GSK
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Email    [email protected]
Tel        +44 20 8047 5502

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.